MI-MAXION-WHEELS
Michelin, one of the world’s largest tire makers and Maxion Wheels, the world’s largest wheel manufacturer, received a 2018 CLEPA Innovation Award at this year’s European Association of Automotive Suppliers (CLEPA) Innovation Award program. The jury recognized the two companies’ joint innovation efforts that resulted in the latest wheel invention, the ACORUS Flexible Wheel, with third place in the “Cooperation” category during the June 13, 2018 award ceremony.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180614006201/en/
Pieter Klinkers, Chief Executive Officer of Maxion Wheels, who accepted the award on behalf of the two companies had this to say, “The automotive industry is undergoing a major transformation and collaboration is key to success in this fast-moving business environment. It not only strengthens and accelerates innovation, it enhances our knowledge and expertise. The ACORUS Flexible Wheel is the result of two global leaders pooling their know-how to deploy the MICHELIN ACORUS Technology into an innovative product for the passenger car market.”
Vincent Rousset-Rouvière, Executive Vice-President of the Original Equipment business line for passenger car tires at Michelin added, “Very early into the project, it became clear that we had to work together with Maxion Wheels and their wheel expertise, to bring this technology to the market quickly.”
Introduced at the IAA Cars 2017 in Frankfurt, Germany, the ACORUS Flexible Wheel is a newly designed wheel-tire combination built to withstand tough road conditions and keep drivers and passengers safe. The patented new technology incorporates two flexible rubber flanges mounted on a special wheel body to create a flexible wheel that improves driving comfort and absorbs impacts from potholes and curbs.
In addition to damage reduction, safety and improved mobility, the ACORUS Flexible Wheel has further benefits for the driver. While improving both comfort and noise levels, there is also an environmental benefit in using MICHELIN ACORUS Technology; the Flexible Wheel is designed to work with any brand of tire, including low rolling resistance tires – meaning lower CO2 emissions and better fuel economy. The innovative wheel solution also means fewer damaged tires and wheels are being thrown away following pothole damage.
The CLEPA Innovation Awards, organised in cooperation with Deloitte and with the support of the Dutch member RAI, celebrate outstanding achievements in the European automotive supply industry in the fields of Environment, Safety, Connectivity and Automation and Cooperation. For the first time, a special prize was awarded in each category to SMEs, acknowledging the important contribution of small and mid-sized companies to the industry’s resourcefulness, ingenuity and competitiveness.
For more information, please visit: https://clepa.eu/events/201806-clepa-innovation-awards/
ABOUT THE EUROPEAN ASSOCIATION OF AUTOMOTIVE SUPPLIERS (CLEPA)
CLEPA is the European Association of Automotive Suppliers. It represents over 3.000 companies supplying state-of-the-art components and innovative technology for safe, smart and sustainable mobility, investing over 20 billion euros yearly in research and development. Automotive suppliers in Europe employ nearly five million people across the continent. Based in Brussels, Belgium, CLEPA is recognized as the natural discussion partner by the European Institutions, United Nations and fellow associations (ACEA, JAMA, MEMA, etc.).
ABOUT MAXION WHEELS
Maxion Wheels, a division of IOCHPE-MAXION S.A., is a leading wheel manufacturer for passenger cars, light trucks, buses, commercial trucks and trailers. The Company also produces wheels for agriculture and military vehicles, as well as other off-highway applications. With more than 100 years of wheel-making experience and 10,000 employees globally, Maxion is the world's largest wheel manufacturer, producing 56 million wheels per year. The Company serves its global OEM customers from 28 locations in 15 countries on five continents, and has state-of-the-art technical centers in the Americas, Europe and Asia.
ABOUT MICHELIN
Michelin, the leading tire company, is dedicated to enhancing its clients’ mobility, sustainably; designing and distributing the most suitable tires, services and solutions for its clients’ needs; providing digital services, maps and guides to help enrich trips and travels and make them unique experiences; and developing high-technology materials that serve the mobility industry. Headquartered in Clermont-Ferrand, France, Michelin is present in 171 countries, has more than 114,000 employees and operates 70 production facilities in 17 countries which together produced around 190 million tires in 2017. (www.michelin.com )
View source version on businesswire.com: https://www.businesswire.com/news/home/20180614006201/en/
Contact:
Maxion Wheels
Colleen Hanley
Global Director, Marketing
and
Communications
Tel: +1 (734) 737-5204
Mobile: +1 (248) 916-2477
Email:
colleen.hanley@maxionwheels.com
or
Michelin
Alain
Ritaly
Media Relations Manager
Mobile: +33 (0)6 67 30 73 34
Email:
alain.ritaly@michelin.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom